NATCO prices generic semaglutide vials from Rs 1,290 a month on the day India's patents lapse

Rs 1,290 is the lowest price in Business Today's report, or rather the only generic price in it, and one price list is a thin basis for calling it a floor ^[1][2]. The outlet itself says the launch sets an "early price benchmark" ^[13] and expects several domestic drugmakers to enter over the next few quarters, a field it says could widen the price range further ^[12]. A rival could match the vial near Rs 1,290 and make it a floor in fact. A rival could undercut it. Or entrants could price pens above it and stretch the range, as the report anticipates. In our view the evidence supports calling it a reference price for the cheapest format and nothing stronger until a competitor posts a number.

NATCO's own comparisons allow one check. The company calls the vial "approximately 70% cheaper than pen devices and nearly 90% lower than the innovator product" ^[9]. Seventy percent off the pen band of Rs 4,000 to Rs 4,500 that NATCO expects in April ^[4] implies a vial between Rs 1,200 and Rs 1,350 ^[10], and the Rs 1,290 entry price sits inside that range ^[2]. Set the same pen band against the top vial price of Rs 1,750 and the discount shrinks to between 56% and 61% ^[11], so we would expect the 70% figure to describe the cheapest strength.

The format is where NATCO has chosen to compete. "This is the first time semaglutide is being offered in a vial format in India," the company said ^[15], and the vials come with customised syringes ^[3]. Business Today notes that vials are more affordable but require careful dosing, while pens are easier to use and cost more ^[7]. The pen, where convenience matters more than price, waits until April.

On the demand side, "As prices correct in India, the addressable market could expand significantly, especially in urban centres," said Rajesh Pherwani, founder and chief investment officer at Valcreate Investment Managers LLP ^[14].

The floor reading fails if a rival lists a vial below Rs 1,290 at a comparable strength, if NATCO's April pen lands under Rs 4,000, or if NATCO cuts its own price. The report does not include rival prices, NATCO's volumes or its margins, so none of those tests can be run yet.